News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Elisabetta Bonzano: Improved efficacy outcomes in early-stage TNBC neoadjuvant ICI therapy
Metastatic Breast Cancer/LinkedIn
Sep 2, 2024, 17:34

Elisabetta Bonzano: Improved efficacy outcomes in early-stage TNBC neoadjuvant ICI therapy

Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X:

“Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer A Systematic Review and Meta-Analysis. 

Neoadjuvant Immunotherapy—From Trials to Practice

Authors: Elizabeth A. Mittendorf, Sara M. Tolaney

Elisabetta Bonzano: Improved efficacy outcomes in early-stage TNBC neoadjuvant ICI therapy

In this meta-analysis involving 5114 patients neoadjuvant ICI therapy was associated with improved efficacy outcomes in early-stage TNBC and PD-L1+ HR+/ERBB2- tumors with an acceptable safety profile. However, in triple-negative breast cancer, no benefit was observed with adjuvant ICI in patients with pCR or residual disease. Given the financial and toxicity costs associated with ICIs, future research should prioritize identifying patients most likely to benefit from the addition of ICIs to neoadjuvant chemotherapy.”

Source: Elisabetta Bonzano/X

Breast Cancer cancer chemotherapy Elisabetta Bonzano Elizabeth A. Mittendorf neoadjuvant ICI OncoDaily Oncology Sara M. Tolaney
Special Coverage
Blog
Jan 20, 2025, 04:32
Bevacizumab and carboplatin-pemetrexed chemotherapy with/out atezolizumab for advanced pleural mesothelioma
Blog
Jan 20, 2025, 04:29
Katsuaki Maehara: Lung EGFR mutations catalog
Opinion
Jan 20, 2025, 04:25
Elisabetta Bonzano: The identification and validation of patient-specific vulnerabilities
Blog
Jan 20, 2025, 04:21
Robin Zon: Behind every diagnosis, test, approval/ disapproval and outcome is a patient and their family
Insight
Jan 20, 2025, 04:14
Laura Bukavina discusses a paper on BCG treatment for patients with urothelial carcinoma of the prostatic urethra
Insight
Jan 20, 2025, 04:00
FDA approved datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
Career
Jan 20, 2025, 03:10
Lawrence “Larry” Deist Appointed to Board of Directors at Rally Foundation for Childhood Cancer Research
Blog
Jan 20, 2025, 02:54
Drew Moghanaki: A new medical oncology position at the VA Medical Center in Long Beach
Science
Jan 20, 2025, 02:44
Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical HL
Science
Jan 20, 2025, 02:16
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer
Blog
Jan 20, 2025, 02:14
Akriti Jain: Grateful to present at Cleveland Clinic ASH review
Career
Jan 19, 2025, 23:12
Kimryn Rathmell Steps Down as NCI Director, Concluding a Pivotal Leadership Era